Grisnilimab
Product Specifications
UNSPSC Description
Grisnilimab (WT1), a IgG2a monoclonal antibody anti-CD7, is a tumor suppressor involved in the etiology of Wilms' tumor. Grisnilimab regulates the transcription of multiple target genes and may participate in the post-transcriptional processing of RNA[1].
Target Antigen
Others
Type
Inhibitory Antibodies
Related Pathways
Others
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/grisnilimab.html
Purity
97.34
Solubility
10 mM in DMSO
Smiles
[Grisnilimab]
References & Citations
[1]Scharnhorst V, et al. WT1 proteins: functions in growth and differentiation. Gene. 2001 Aug 8;273(2):141-61.|[2]Hertler AA, et al. An immunotoxin for the treatment of T-acute lymphoblastic leukemic meningitis: studies in rhesus monkeys. Cancer Immunol Immunother. 1989;28(1):59-66.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P99650/Grisnilimab-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P99650/Grisnilimab-SDS-MedChemExpress.pdf
Clinical Information
Phase 2
CAS Number
2367001-70-3
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
